NeoGenomics (NEO) Financials

$6.21 +0.01 (+0.16%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$6.18 -0.03 (-0.48%)

As of 08/15/2025 06:17 PM Eastern

Annual Income Statements for NeoGenomics

This table shows NeoGenomics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	1.13	-2.66	-31	-11	6.09	8.01	4.17	-8.35	-144	-88	-79
Consolidated Net Income / (Loss)	1.13	-2.54	-6.14	-0.40	2.64	8.01	4.17	-8.35	-144	-88	-79
Net Income / (Loss) Continuing Operations	1.13	-2.54	-6.14	-0.40	2.64	8.01	4.17	-8.35	-144	-88	-79
Total Pre-Tax Income	1.29	-4.49	-7.84	-2.65	3.82	3.65	-14	-15	-159	-97	-81
Total Operating Income	2.22	-5.64	2.16	2.90	10	13	-14	-119	-158	-108	-92
Total Gross Profit	41	44	98	102	127	197	186	187	188	245	290
Total Revenue	87	100	232	240	277	409	444	484	510	592	661
Operating Revenue	87	100	232	240	277	409	444	484	510	592	661
Total Cost of Revenue	46	56	134	138	149	212	259	297	322	347	370
Operating Cost of Revenue	46	56	134	138	149	212	259	297	322	347	370
Total Operating Expenses	38	49	96	99	117	184	200	306	346	352	382
Selling, General & Admin Expense	24	34	64	70	85	128	144	221	243	243	260
Marketing Expense	12	12	24	24	29	47	48	63	67	71	85
Research & Development Expense	2.69	4.20	4.65	3.64	3.00	8.49	8.23	22	30	27	31
Restructuring Charge	-	-	-	-	-	-	0.00	0.00	4.52	11	6.66
Total Other Income / (Expense), net	-0.93	1.15	-10.00	-5.55	-6.22	-9.36	-0.06	104	-1.72	11	11
Interest Expense	0.99	0.85	10.00	5.54	6.23	4.73	12	8.22	7.58	6.91	6.62
Interest & Investment Income	-	-	-	-	-	-	-	3.14	6.08	17	18
Other Income / (Expense), net	0.06	2.00	0.00	-0.01	0.01	-4.63	12	109	-0.21	0.64	-0.38
Income Tax Expense	0.16	-1.95	-1.70	-2.25	1.18	-4.36	-18	-6.73	-15	-9.13	-1.95
Basic Earnings per Share	$0.02	($0.04)	($0.40)	($0.14)	$0.07	$0.08	-	-	($1.16)	($0.70)	($0.62)
Weighted Average Basic Shares Outstanding	53.48M	60.53M	77.54M	79.43M	85.62M	100.47M	108.58M	119.96M	124.22M	125.50M	126.66M
Diluted Earnings per Share	$0.02	($0.04)	($0.40)	($0.14)	$0.07	$0.08	-	-	($1.16)	($0.70)	($0.62)
Weighted Average Diluted Shares Outstanding	56.02M	60.53M	77.54M	79.43M	91.57M	103.62M	111.79M	119.96M	124.22M	125.50M	126.66M
Weighted Average Basic & Diluted Shares Outstanding	56.60M	66.40M	78.82M	80.51M	94.57M	104.83M	116.94M	124.03M	127.46M	127.61M	128.46M

This table shows NeoGenomics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025
Period end date	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025
Net Income / (Loss) Attributable to Common Shareholders	-23	-31	-24	-19	-14	-27	-19	-18	-15	-26	-45
Consolidated Net Income / (Loss)	-23	-31	-24	-19	-14	-27	-19	-18	-15	-26	-45
Net Income / (Loss) Continuing Operations	-23	-31	-24	-19	-14	-27	-19	-18	-15	-26	-45
Total Pre-Tax Income	-26	-34	-27	-21	-15	-28	-19	-18	-16	-26	-46
Total Operating Income	-26	-35	-30	-24	-19	-31	-22	-21	-18	-28	-48
Total Gross Profit	57	55	60	62	68	65	72	75	77	73	77
Total Revenue	139	137	147	152	156	156	165	168	172	168	181
Operating Revenue	139	137	147	152	156	156	165	168	172	168	181
Total Cost of Revenue	82	82	87	90	88	91	92	93	95	95	104
Operating Cost of Revenue	82	82	87	90	88	91	92	93	95	95	104
Total Operating Expenses	83	90	90	87	86	96	94	96	96	101	125
Selling, General & Admin Expense	55	62	60	61	60	66	63	67	64	68	72
Marketing Expense	17	16	19	18	18	20	22	20	22	23	24
Research & Development Expense	6.68	7.40	7.50	5.29	7.13	7.62	7.89	7.68	7.97	10	9.02
Impairment Charge	-	-	-	-	-	-	0.00	-	-	-	20
Restructuring Charge	4.52	4.68	3.07	2.13	1.21	2.40	1.54	1.01	1.71	0.00	0.00
Total Other Income / (Expense), net	0.86	1.35	3.25	2.74	3.29	2.89	2.92	3.35	2.27	2.17	1.81
Interest Expense	5.22	1.76	1.78	1.69	1.68	1.69	1.67	1.64	1.62	1.62	0.93
Interest & Investment Income	-	3.22	4.31	4.53	4.85	4.83	4.59	4.67	4.33	3.72	2.26
Other Income / (Expense), net	-0.00	-0.11	0.73	-0.10	0.12	-0.26	-0.00	0.32	-0.43	0.07	0.48
Income Tax Expense	-2.84	-2.93	-2.31	-2.94	-0.96	-0.62	-0.38	-0.15	-0.80	0.27	-0.72
Weighted Average Basic Shares Outstanding	124.22M	125.03M	125.36M	125.69M	125.50M	126.11M	126.41M	126.95M	126.66M	127.38M	127.95M
Weighted Average Diluted Shares Outstanding	124.22M	125.03M	125.36M	125.69M	125.50M	126.11M	126.41M	126.95M	126.66M	127.38M	127.95M
Weighted Average Basic & Diluted Shares Outstanding	127.46M	127.58M	127.55M	127.47M	127.61M	127.71M	128.16M	128.36M	128.46M	128.69M	129.18M

This table details how cash moves in and out of NeoGenomics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	29	-10	-11	0.30	-3.01	163	78	66	-54	79	25
Net Cash From Operating Activities	9.45	6.39	21	18	45	23	1.46	-27	-66	-1.95	7.02
Net Cash From Continuing Operating Activities	9.45	6.39	21	18	45	23	1.46	-27	-66	-1.95	7.02
Net Income / (Loss) Continuing Operations	1.13	-2.54	-6.14	-0.40	2.64	8.01	4.17	-8.35	-144	-88	-79
Consolidated Net Income / (Loss)	1.13	-2.54	-6.14	-0.40	2.64	8.01	4.17	-8.35	-144	-88	-79
Depreciation Expense	5.35	6.73	16	16	16	20	26	30	35	37	39
Amortization Expense	0.36	0.41	11	7.44	6.47	10	14	26	37	38	36
Non-Cash Adjustments To Reconcile Net Income	3.13	3.73	10	7.75	7.36	17	-6.35	-84	36	28	37
Changes in Operating Assets and Liabilities, net	-0.52	-1.95	-9.09	-12	13	-32	-37	10	-30	-18	-26
Net Cash From Investing Activities	-9.60	-75	-6.50	-14	-140	-20	-159	-632	0.52	77	13
Net Cash From Continuing Investing Activities	-9.60	-75	-6.50	-14	-140	-20	-159	-632	0.52	77	13
Purchase of Property, Plant & Equipment	-3.77	-2.22	-7.54	-14	-14	-20	-29	-64	-31	-29	-41
Purchase of Investments	-	-	-	-	0.00	0.00	-99	-212	-98	-6.76	0.00
Sale of Property, Plant & Equipment	-	-	-	-	-	-	0.00	0.00	12	0.00	0.00
Sale and/or Maturity of Investments	-	-	-	-	0.00	0.00	5.36	63	117	112	54
Net Cash From Financing Activities	29	58	-26	-4.10	92	159	236	725	12	4.55	4.65
Net Cash From Continuing Financing Activities	29	58	-26	-4.10	92	159	236	725	12	4.55	4.65
Issuance of Common Equity	37	0.94	3.77	2.59	9.02	11	20	15	13	4.62	4.65
Other Financing Activities, net	-	-	-	-5.42	-6.56	-7.20	-8.93	-32	-0.76	-0.07	0.00
Cash Interest Paid	0.98	0.91	5.42	5.16	6.51	4.78	2.93	3.07	3.40	3.38	3.83
Cash Income Taxes Paid	0.18	0.03	0.29	0.28	-0.03	0.32	0.25	0.15	0.18	0.18	0.21

This table details how cash moves in and out of NeoGenomics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025
Period end date	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025
Net Change in Cash & Equivalents	-2.95	12	13	17	36	-11	23	6.91	5.02	-21	-191
Net Cash From Operating Activities	-3.69	-13	-1.55	-5.50	18	-26	14	9.25	9.80	-25	20
Net Cash From Continuing Operating Activities	-3.69	-13	-1.55	-5.50	18	-26	14	9.25	9.80	-25	20
Net Income / (Loss) Continuing Operations	-23	-31	-24	-19	-14	-27	-19	-18	-15	-26	-45
Consolidated Net Income / (Loss)	-23	-31	-24	-19	-14	-27	-19	-18	-15	-26	-45
Depreciation Expense	9.48	9.05	9.48	9.35	9.58	9.91	9.75	9.62	9.83	9.37	9.14
Amortization Expense	9.30	9.50	9.50	9.51	9.51	9.09	9.09	9.09	9.09	9.10	8.62
Non-Cash Adjustments To Reconcile Net Income	15	6.29	7.19	13	1.70	8.89	13	6.48	8.53	11	35
Changes in Operating Assets and Liabilities, net	-14	-6.73	-3.38	-19	11	-27	0.85	1.76	-2.32	-29	13
Net Cash From Investing Activities	-1.06	24	15	21	17	15	7.31	-3.52	-5.47	3.56	-9.31
Net Cash From Continuing Investing Activities	-1.06	24	15	21	17	15	7.31	-3.52	-5.47	3.56	-9.31
Purchase of Property, Plant & Equipment	-4.53	-9.93	-7.49	-4.27	-7.06	-5.59	-13	-11	-12	-4.50	-6.32
Sale and/or Maturity of Investments	27	40	22	25	24	20	20	7.28	6.13	8.06	3.00
Net Cash From Financing Activities	1.80	1.38	0.06	1.84	1.27	0.82	1.97	1.18	0.69	0.95	-202
Net Cash From Continuing Financing Activities	1.80	1.38	0.06	1.84	1.27	0.82	1.97	1.18	0.69	0.95	-202
Issuance of Common Equity	1.85	1.41	0.09	1.85	1.27	0.82	1.97	1.18	0.69	0.95	-1.18
Cash Interest Paid	1.26	0.43	1.26	0.43	1.26	0.43	1.26	0.45	1.69	0.00	1.26
Cash Income Taxes Paid	0.03	0.00	0.18	-	-	0.09	0.09	0.14	-0.11	0.00	0.46

This table presents NeoGenomics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	81	351	337	344	505	710	988	1,870	1,740	1,681	1,638
Total Current Assets	59	82	79	86	104	291	449	682	605	597	596
Cash & Equivalents	34	23	13	13	9.81	173	229	317	263	342	367
Short-Term Investments	-	-	-	-	-	0.00	68	-	175	73	20
Accounts Receivable	20	49	56	60	77	94	107	112	120	131	151
Inventories, net	2.62	5.11	6.25	7.47	8.65	14	30	23	24	24	27
Prepaid Expenses	1.14	4.89	4.54	4.15	7.73	6.33	12	12	15	18	20
Other Current Assets	-	-	-	1.00	0.56	2.75	4.56	18	8.08	8.24	12
Plant, Property, & Equipment, net	15	35	34	37	61	64	86	109	102	92	94
Total Noncurrent Assets	7.28	234	224	222	340	355	454	1,079	1,032	992	948
Goodwill	2.93	146	147	147	198	199	211	527	523	523	523
Intangible Assets	4.21	88	77	74	140	127	121	442	408	373	340
Other Noncurrent Operating Assets	0.14	0.13	0.17	0.89	2.54	29	92	109	101	97	85
Total Liabilities & Shareholders' Equity	81	351	337	344	505	710	988	1,870	1,740	1,681	1,638
Total Liabilities	21	113	151	140	185	202	294	762	742	740	736
Total Current Liabilities	15	40	38	36	61	64	73	87	90	96	301
Short-Term Debt	3.22	14	8.73	8.99	7.87	5.00	-	-	-	0.00	201
Accounts Payable	6.29	12	17	10	18	20	25	18	21	20	22
Accrued Expenses	1.21	7.37	4.25	6.14	8.99	7.55	12	18	15	15	13
Current Deferred Revenue	-	-	-	-	-	1.61	4.03	5.19	7.56	2.13	0.41
Current Employee Benefit Liabilities	3.90	6.22	8.35	9.48	19	21	25	38	40	53	62
Other Current Liabilities	0.00	-	-	1.41	7.23	8.81	7.81	8.02	6.65	5.61	3.38
Other Current Nonoperating Liabilities	-	-	-	-	-	-	-	-	-	-	0.00
Total Noncurrent Liabilities	6.08	73	112	103	124	138	221	674	652	643	434
Long-Term Debt	0.06	52	92	91	98	92	168	532	535	538	340
Noncurrent Deferred & Payable Income Tax Liabilities	0.82	16	15	6.69	22	16	5.42	55	35	24	22
Other Noncurrent Operating Liabilities	-	-	-	0.28	3.06	31	47	86	82	81	73
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	60	210	164	172	320	507	694	1,108	998	942	902
Total Preferred & Common Equity	60	210	164	172	320	507	694	1,108	998	942	902
Total Common Equity	60	210	164	172	320	507	694	1,108	998	942	902
Common Stock	80	232	216	230	340	520	701	1,124	1,161	1,190	1,228
Retained Earnings	-19	-22	-52	-58	-19	-11	-7.19	-15	-159	-247	-326
Accumulated Other Comprehensive Income / (Loss)	-	-	0.00	0.27	-0.58	-1.62	0.01	-0.64	-3.90	-1.67	-0.21

This table presents NeoGenomics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2022	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025
Period end date	6/30/2022	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025
Total Assets	1,792	1,756	1,709	1,695	1,678	1,640	1,643	1,641	1,601	1,394
Total Current Assets	622	603	585	585	587	574	584	590	574	393
Cash & Equivalents	284	266	276	289	306	332	355	362	346	155
Short-Term Investments	182	177	142	120	96	53	33	26	12	8.96
Accounts Receivable	111	112	119	125	133	140	147	151	151	153
Inventories, net	22	24	24	25	24	20	23	24	30	34
Prepaid Expenses	17	17	16	17	19	19	17	18	23	23
Other Current Assets	6.51	7.52	7.62	8.43	9.32	9.31	9.16	8.31	12	19
Plant, Property, & Equipment, net	111	107	103	100	95	88	92	93	90	85
Total Noncurrent Assets	1,059	1,045	1,021	1,010	997	979	967	958	938	916
Goodwill	527	523	523	523	523	523	523	523	523	524
Intangible Assets	425	417	399	391	382	365	356	348	331	302
Other Noncurrent Operating Assets	106	106	99	97	92	91	88	87	84	90
Total Liabilities & Shareholders' Equity	1,792	1,756	1,709	1,695	1,678	1,640	1,643	1,641	1,601	1,394
Total Liabilities	749	743	735	739	731	717	727	733	713	540
Total Current Liabilities	83	85	87	95	93	77	290	296	280	100
Short-Term Debt	-	-	-	-	-	-	200	200	201	0.00
Accounts Payable	17	14	23	18	17	18	17	17	16	27
Accrued Expenses	16	20	18	18	19	18	17	23	19	18
Current Deferred Revenue	6.35	6.39	6.07	5.71	3.62	1.14	0.97	0.59	1.16	1.08
Current Employee Benefit Liabilities	37	38	33	46	48	35	51	52	39	49
Other Current Liabilities	6.12	6.50	6.97	7.37	6.22	4.49	3.57	3.72	3.08	4.05
Other Current Nonoperating Liabilities	-	-	-	-	-	-	-	-	-	0.46
Total Noncurrent Liabilities	666	658	648	644	638	640	437	436	433	440
Long-Term Debt	534	535	536	537	537	539	340	340	341	341
Noncurrent Deferred & Payable Income Tax Liabilities	46	38	32	29	25	23	23	23	21	20
Other Noncurrent Operating Liabilities	86	85	80	79	75	78	75	74	72	79
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,044	1,013	974	956	947	923	916	908	888	854
Total Preferred & Common Equity	1,044	1,013	974	956	947	923	916	908	888	854
Total Common Equity	1,044	1,013	974	956	947	923	916	908	888	854
Common Stock	1,147	1,154	1,167	1,173	1,182	1,199	1,210	1,219	1,240	1,251
Retained Earnings	-100	-136	-190	-214	-233	-274	-293	-310	-352	-397
Accumulated Other Comprehensive Income / (Loss)	-4.06	-5.10	-2.83	-2.57	-1.85	-1.33	-1.02	-0.64	-0.06	0.03

This table displays calculated financial ratios and metrics derived from NeoGenomics' official financial filings.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	31.00%	14.62%	132.27%	3.64%	15.19%	47.73%	8.71%	8.97%	5.24%	16.07%	11.65%
EBITDA Growth	4.52%	-56.05%	722.95%	-10.19%	24.72%	20.75%	-2.37%	20.96%	-285.61%	63.03%	46.18%
EBIT Growth	-28.36%	-259.85%	159.28%	34.11%	247.89%	-16.69%	-125.44%	-368.93%	-1,479.47%	32.15%	13.64%
NOPAT Growth	-34.04%	-302.51%	138.24%	34.66%	241.21%	312.14%	-134.29%	-748.73%	-32.73%	31.65%	14.51%
Net Income Growth	-44.32%	-323.94%	-142.29%	93.55%	766.67%	203.26%	-47.89%	-300.07%	-1,628.17%	39.02%	10.51%
EPS Growth	-50.00%	-300.00%	-900.00%	65.00%	150.00%	14.29%	0.00%	0.00%	0.00%	39.66%	11.43%
Operating Cash Flow Growth	324.34%	-32.35%	235.95%	-16.02%	148.30%	-47.82%	-93.75%	-1,930.34%	-146.95%	97.04%	459.60%
Free Cash Flow Firm Growth	-89.55%	-4,139.80%	102.88%	-303.13%	-654.76%	112.42%	-923.80%	-483.38%	88.05%	44.48%	-26.82%
Invested Capital Growth	29.22%	712.77%	-2.04%	6.04%	40.20%	3.50%	24.44%	109.72%	-2.67%	-2.81%	-0.74%
Revenue Q/Q Growth	8.31%	2.34%	9.93%	5.82%	5.75%	8.03%	4.50%	-0.05%	2.61%	2.93%	2.55%
EBITDA Q/Q Growth	7.13%	-54.19%	46.37%	16.33%	-1.34%	3.87%	58.75%	-51.78%	16.84%	20.66%	-3.31%
EBIT Q/Q Growth	8.13%	-503.89%	632.99%	169.50%	-7.60%	-0.61%	83.06%	-121.83%	9.26%	6.90%	-0.41%
NOPAT Q/Q Growth	10.71%	-2,354.36%	632.99%	169.79%	-55.94%	167.80%	18.70%	12.81%	8.79%	6.76%	0.19%
Net Income Q/Q Growth	20.17%	-776.00%	-350.95%	96.58%	-61.39%	288.08%	184.30%	-117.09%	11.68%	8.68%	-1.28%
EPS Q/Q Growth	0.00%	-500.00%	-66.67%	61.11%	-22.22%	300.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	18.73%	21.59%	-9.91%	49.85%	27.62%	-34.10%	225.21%	-2,677.86%	19.60%	91.66%	-53.20%
Free Cash Flow Firm Q/Q Growth	24.10%	-5,078.49%	103.03%	0.00%	-979.07%	112.56%	2.60%	3.75%	18.63%	25.01%	-32.33%
Invested Capital Q/Q Growth	6.44%	656.22%	-0.10%	1.60%	41.02%	3.31%	2.48%	-0.08%	-0.79%	-1.67%	-0.39%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	46.76%	43.84%	42.32%	42.44%	45.99%	48.15%	41.83%	38.62%	36.86%	41.34%	43.92%
EBITDA Margin	9.17%	3.51%	12.45%	10.79%	11.68%	9.55%	8.58%	9.52%	-16.79%	-5.35%	-2.58%
Operating Margin	2.55%	-5.65%	0.93%	1.21%	3.63%	3.18%	-3.15%	-24.52%	-30.92%	-18.21%	-13.94%
EBIT Margin	2.61%	-3.64%	0.93%	1.20%	3.63%	2.05%	-0.48%	-2.06%	-30.96%	-18.10%	-14.00%
Profit (Net Income) Margin	1.30%	-2.54%	-2.65%	-0.16%	0.95%	1.96%	0.94%	-1.72%	-28.30%	-14.87%	-11.92%
Tax Burden Percent	87.82%	56.47%	78.31%	14.94%	69.04%	219.64%	-29.68%	55.37%	90.53%	90.60%	97.58%
Interest Burden Percent	56.68%	123.49%	-363.94%	-91.70%	38.03%	43.52%	659.60%	150.86%	100.95%	90.67%	87.23%
Effective Tax Rate	12.18%	0.00%	0.00%	0.00%	30.96%	-119.64%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	6.24%	-2.46%	0.53%	0.70%	1.94%	6.74%	-2.02%	-10.00%	-9.94%	-6.98%	-6.08%
ROIC Less NNEP Spread (ROIC-NNEP)	14.53%	9.94%	-10.27%	-1.90%	-2.60%	-198.82%	-13.97%	-116.38%	-69.21%	-18.38%	-16.36%
Return on Net Nonoperating Assets (RNNOA)	-3.48%	0.76%	-3.43%	-0.91%	-0.94%	-4.80%	2.72%	9.08%	-3.76%	-2.09%	-2.46%
Return on Equity (ROE)	2.76%	-1.70%	-2.89%	-0.20%	1.01%	1.93%	0.69%	-0.93%	-13.70%	-9.07%	-8.54%
Cash Return on Invested Capital (CROIC)	-19.25%	-158.63%	2.59%	-5.16%	-31.53%	3.30%	-23.80%	-80.86%	-7.23%	-4.13%	-5.33%
Operating Return on Assets (OROA)	3.76%	-1.68%	0.63%	0.85%	2.37%	1.38%	-0.25%	-0.70%	-8.74%	-6.26%	-5.57%
Return on Assets (ROA)	1.87%	-1.17%	-1.78%	-0.12%	0.62%	1.32%	0.49%	-0.58%	-7.99%	-5.14%	-4.74%
Return on Common Equity (ROCE)	2.76%	-1.54%	-2.54%	-0.17%	0.94%	1.93%	0.69%	-0.93%	-13.70%	-9.07%	-8.54%
Return on Equity Simple (ROE_SIMPLE)	1.87%	-1.21%	-3.75%	-0.23%	0.82%	1.58%	0.60%	-0.75%	-14.45%	-9.34%	-8.72%
Net Operating Profit after Tax (NOPAT)	1.95	-3.94	1.51	2.03	6.93	29	-9.79	-83	-110	-75	-64
NOPAT Margin	2.24%	-3.95%	0.65%	0.85%	2.50%	6.99%	-2.20%	-17.16%	-21.65%	-12.75%	-9.76%
Net Nonoperating Expense Percent (NNEP)	-8.29%	-12.39%	10.81%	2.61%	4.55%	205.56%	11.94%	106.37%	59.28%	11.39%	10.28%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	-7.20%	-5.10%	-4.47%
Cost of Revenue to Revenue	53.24%	56.16%	57.68%	57.56%	54.01%	51.85%	58.17%	61.38%	63.14%	58.66%	56.08%
SG&A Expenses to Revenue	27.34%	33.70%	27.58%	29.29%	30.65%	31.31%	32.35%	45.70%	47.74%	41.09%	39.32%
R&D to Revenue	3.09%	4.21%	2.01%	1.51%	1.08%	2.08%	1.85%	4.52%	5.95%	4.62%	4.72%
Operating Expenses to Revenue	44.21%	49.49%	41.39%	41.23%	42.36%	44.96%	44.97%	63.14%	67.79%	59.55%	57.86%
Earnings before Interest and Taxes (EBIT)	2.27	-3.64	2.16	2.89	10	8.38	-2.13	-9.99	-158	-107	-92
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	7.98	3.51	29	26	32	39	38	46	-86	-32	-17
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.14	2.27	4.11	4.14	3.66	6.02	8.61	3.79	1.17	2.19	2.34
Price to Tangible Book Value (P/TBV)	4.70	0.00	0.00	0.00	0.00	16.76	16.49	30.26	17.42	45.19	53.03
Price to Revenue (P/Rev)	2.87	4.76	2.90	2.97	4.24	7.47	13.45	8.67	2.29	3.49	3.20
Price to Earnings (P/E)	220.92	0.00	0.00	0.00	192.66	381.45	1,432.85	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.45%	0.00%	0.00%	0.00%	0.52%	0.26%	0.07%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	6.39	1.93	2.82	2.82	3.05	6.91	10.85	3.92	1.15	2.05	2.15
Enterprise Value to Revenue (EV/Rev)	2.58	5.53	3.41	3.49	4.59	7.28	13.10	9.12	2.48	3.69	3.44
Enterprise Value to EBITDA (EV/EBITDA)	28.18	157.26	27.35	32.32	39.26	76.28	152.71	95.80	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	98.89	0.00	366.30	289.84	126.23	355.51	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	115.45	0.00	523.28	412.35	183.10	104.24	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	23.80	86.27	36.75	46.44	28.34	127.42	3,986.40	0.00	0.00	0.00	323.17
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	107.55	0.00	0.00	212.99	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.14	0.30	0.57	0.52	0.33	0.19	0.24	0.48	0.54	0.57	0.60
Long-Term Debt to Equity	0.09	0.24	0.52	0.47	0.31	0.18	0.24	0.48	0.54	0.57	0.38
Financial Leverage	-0.24	0.08	0.33	0.48	0.36	0.02	-0.19	-0.08	0.05	0.11	0.15
Leverage Ratio	1.47	1.45	1.62	1.74	1.62	1.47	1.41	1.59	1.71	1.76	1.80
Compound Leverage Factor	0.84	1.79	-5.90	-1.60	0.62	0.64	9.32	2.39	1.73	1.60	1.57
Debt to Total Capital	12.31%	23.06%	36.26%	34.01%	24.86%	16.03%	19.49%	32.45%	34.91%	36.37%	37.49%
Short-Term Debt to Total Capital	4.68%	4.52%	2.98%	2.90%	1.85%	0.83%	0.00%	0.00%	0.00%	0.00%	13.91%
Long-Term Debt to Total Capital	7.63%	18.54%	33.28%	31.11%	23.01%	15.20%	19.49%	32.45%	34.91%	36.37%	23.58%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	9.24%	7.81%	10.52%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	87.69%	67.70%	55.92%	55.47%	75.14%	83.98%	80.51%	67.55%	65.09%	63.63%	62.51%
Debt to EBITDA	1.06	20.35	3.68	4.07	3.28	2.48	4.41	11.55	-6.26	-17.01	-31.79
Net Debt to EBITDA	-3.16	13.68	3.24	3.57	2.98	-1.95	-4.14	4.68	-1.14	-3.89	-9.06
Long-Term Debt to EBITDA	0.66	16.36	3.38	3.72	3.04	2.35	4.41	11.55	-6.26	-17.01	-19.99
Debt to NOPAT	4.35	-18.10	70.38	51.90	15.29	3.39	-17.16	-6.41	-4.85	-7.14	-8.39
Net Debt to NOPAT	-12.94	-12.16	62.08	45.59	13.88	-2.67	16.10	-2.59	-0.88	-1.63	-2.39
Long-Term Debt to NOPAT	2.70	-14.55	64.59	47.47	14.16	3.21	-17.16	-6.41	-4.85	-7.14	-5.28
Altman Z-Score	8.73	2.82	3.32	3.72	4.47	10.04	13.09	3.92	1.16	1.97	1.88
Noncontrolling Interest Sharing Ratio	0.00%	9.58%	12.12%	14.19%	6.21%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.02	2.06	2.07	2.35	1.70	4.55	6.13	7.81	6.73	6.20	1.98
Quick Ratio	3.70	1.81	1.79	2.01	1.42	4.18	5.51	4.92	6.20	5.67	1.78
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-6.01	-255	7.34	-15	-113	14	-115	-672	-80	-45	-57
Operating Cash Flow to CapEx	250.53%	288.62%	284.99%	131.75%	312.97%	116.68%	5.02%	-41.66%	-351.16%	-6.79%	17.10%
Free Cash Flow to Firm to Interest Expense	-6.10	-298.38	0.73	-2.69	-18.06	2.96	-9.66	-81.74	-10.60	-6.46	-8.55
Operating Cash Flow to Interest Expense	9.59	7.49	2.15	3.26	7.19	4.94	0.12	-3.25	-8.71	-0.28	1.06
Operating Cash Flow Less CapEx to Interest Expense	5.76	4.89	1.39	0.78	4.89	0.71	-2.32	-11.05	-11.18	-4.45	-5.14
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.44	0.46	0.67	0.71	0.65	0.67	0.52	0.34	0.28	0.35	0.40
Accounts Receivable Turnover	4.45	2.88	4.44	4.14	4.03	4.78	4.42	4.42	4.40	4.72	4.69
Inventory Turnover	18.86	14.51	23.54	20.15	18.54	18.39	11.77	11.23	13.50	14.33	14.56
Fixed Asset Turnover	7.03	4.02	6.76	6.81	5.68	6.54	5.92	4.96	4.81	6.08	7.10
Accounts Payable Turnover	8.85	5.98	9.14	10.16	10.59	11.35	11.61	13.86	16.75	16.99	17.67
Days Sales Outstanding (DSO)	82.01	126.94	82.24	88.07	90.57	76.41	82.57	82.51	83.01	77.41	77.85
Days Inventory Outstanding (DIO)	19.36	25.15	15.51	18.11	19.69	19.85	31.01	32.49	27.03	25.47	25.08
Days Payable Outstanding (DPO)	41.22	61.08	39.92	35.94	34.47	32.15	31.43	26.33	21.79	21.48	20.66
Cash Conversion Cycle (CCC)	60.15	91.01	57.82	70.25	75.80	64.10	82.14	88.67	88.25	81.40	82.26
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	35	286	280	297	417	431	537	1,125	1,095	1,065	1,057
Invested Capital Turnover	2.79	0.62	0.82	0.83	0.78	0.96	0.92	0.58	0.46	0.55	0.62
Increase / (Decrease) in Invested Capital	7.96	251	-5.83	17	119	15	105	589	-30	-31	-7.93
Enterprise Value (EV)	225	552	789	838	1,269	2,978	5,820	4,417	1,264	2,185	2,270
Market Capitalization	250	475	673	712	1,173	3,054	5,978	4,201	1,167	2,062	2,115
Book Value per Share	$1.01	$3.47	$2.09	$2.14	$3.45	$4.86	$6.25	$9.00	$7.90	$7.39	$7.03
Tangible Book Value per Share	$0.89	($0.41)	($0.77)	($0.61)	($0.19)	$1.74	$3.27	$1.13	$0.53	$0.36	$0.31
Total Capital	69	309	293	310	426	604	862	1,641	1,533	1,480	1,443
Total Debt	8.48	71	106	105	106	97	168	532	535	538	541
Total Long-Term Debt	5.26	57	97	96	98	92	168	532	535	538	340
Net Debt	-25	48	94	93	96	-76	-158	216	97	123	154
Capital Expenditures (CapEx)	3.77	2.22	7.54	14	14	20	29	64	19	29	41
Debt-free, Cash-free Net Working Capital (DFCFNWC)	14	33	37	46	41	59	79	277	77	85	109
Debt-free Net Working Capital (DFNWC)	47	56	49	58	51	232	376	594	515	501	496
Net Working Capital (NWC)	44	42	41	49	43	227	376	594	515	501	295
Net Nonoperating Expense (NNE)	0.82	-1.41	7.65	2.43	4.29	21	-14	-75	34	13	14
Net Nonoperating Obligations (NNO)	-25	48	94	93	96	-76	-158	17	97	123	154
Total Depreciation and Amortization (D&A)	5.71	7.14	27	23	22	31	40	56	72	75	75
Debt-free, Cash-free Net Working Capital to Revenue	15.68%	32.95%	15.93%	18.97%	14.74%	14.39%	17.84%	57.29%	15.18%	14.42%	16.46%
Debt-free Net Working Capital to Revenue	54.37%	56.42%	21.33%	24.31%	18.29%	56.71%	84.50%	122.70%	101.10%	84.60%	75.02%
Net Working Capital to Revenue	50.67%	42.39%	17.56%	20.56%	15.45%	55.48%	84.50%	122.70%	101.10%	84.60%	44.63%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.02	$0.00	($0.39)	$0.00	$0.07	$0.08	$0.04	($0.07)	$0.00	$0.00	($0.62)
Adjusted Weighted Average Basic Shares Outstanding	53.48M	0.00	77.54M	79.43M	85.62M	100.47M	108.58M	119.96M	124.22M	125.50M	126.66M
Adjusted Diluted Earnings per Share	$0.02	$0.00	($0.39)	$0.00	$0.07	$0.08	$0.04	($0.07)	$0.00	$0.00	($0.62)
Adjusted Weighted Average Diluted Shares Outstanding	56.02M	0.00	77.54M	79.43M	91.57M	103.62M	111.79M	119.96M	124.22M	125.50M	126.66M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	60.26M	0.00	78.82M	80.51M	94.57M	104.83M	116.94M	124.03M	127.46M	127.61M	128.46M
Normalized Net Operating Profit after Tax (NOPAT)	1.95	-3.94	3.93	2.03	6.93	9.10	-9.79	-83	-107	-68	-60
Normalized NOPAT Margin	2.24%	-3.95%	1.70%	0.85%	2.50%	2.23%	-2.20%	-17.16%	-21.03%	-11.43%	-9.05%
Pre Tax Income Margin	1.48%	-4.50%	-3.38%	-1.10%	1.38%	0.89%	-3.16%	-3.11%	-31.26%	-16.41%	-12.21%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	2.31	-4.26	0.22	0.52	1.61	1.77	-0.18	-1.22	-20.82	-15.50	-13.98
NOPAT to Interest Expense	1.98	-4.62	0.15	0.37	1.11	6.04	-0.82	-10.11	-14.55	-10.92	-9.74
EBIT Less CapEx to Interest Expense	-1.52	-6.85	-0.54	-1.95	-0.68	-2.46	-2.62	-9.02	-23.30	-19.67	-20.18
NOPAT Less CapEx to Interest Expense	-1.85	-7.21	-0.60	-2.10	-1.18	1.80	-3.26	-17.92	-17.03	-15.08	-15.95
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from NeoGenomics' official financial filings.

Metric	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025
Period end date	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	10.32%	17.11%	17.47%	17.99%	12.15%	13.86%	11.97%	10.44%	10.57%	7.55%	10.23%
EBITDA Growth	69.50%	51.44%	54.48%	74.49%	108.32%	28.86%	69.48%	60.18%	-86.10%	21.46%	-845.13%
EBIT Growth	37.91%	32.15%	27.28%	38.48%	30.07%	12.38%	24.76%	14.04%	-2.07%	9.96%	-114.86%
NOPAT Growth	36.53%	32.59%	24.70%	38.76%	29.60%	12.85%	26.60%	12.39%	0.93%	8.97%	-117.07%
Net Income Growth	45.67%	37.67%	31.08%	49.76%	36.85%	12.13%	23.38%	4.41%	-6.97%	4.21%	-141.88%
EPS Growth	0.00%	37.50%	0.00%	50.00%	0.00%	16.00%	0.00%	6.67%	0.00%	4.76%	0.00%
Operating Cash Flow Growth	81.37%	56.29%	90.89%	66.22%	582.61%	-104.18%	997.42%	268.20%	-44.89%	2.27%	46.34%
Free Cash Flow Firm Growth	101.87%	101.55%	121.98%	183.01%	54.36%	-165.60%	-91.88%	56.74%	-127.81%	-121.80%	331.99%
Invested Capital Growth	-2.67%	-3.03%	-2.51%	-1.94%	-2.81%	-1.38%	-1.47%	-2.02%	-0.74%	-0.51%	-3.35%
Revenue Q/Q Growth	7.71%	-1.07%	7.07%	3.43%	2.37%	0.44%	5.29%	2.02%	2.49%	-2.31%	7.91%
EBITDA Q/Q Growth	64.32%	-118.85%	38.78%	46.63%	111.64%	-1,970.14%	73.74%	30.36%	104.06%	-10,664.77%	-216.06%
EBIT Q/Q Growth	33.18%	-33.36%	17.12%	16.71%	24.05%	-67.10%	28.83%	4.84%	9.81%	-47.41%	-69.83%
NOPAT Q/Q Growth	33.22%	-32.94%	14.77%	19.06%	23.23%	-64.57%	28.22%	3.39%	13.19%	-51.21%	-71.17%
Net Income Q/Q Growth	38.44%	-35.74%	20.99%	23.90%	22.63%	-88.89%	31.11%	5.06%	13.42%	-69.17%	-73.95%
EPS Q/Q Growth	40.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	77.35%	-244.42%	87.80%	-255.10%	423.52%	-245.72%	153.61%	-33.44%	5.99%	-358.44%	180.27%
Free Cash Flow Firm Q/Q Growth	313.85%	-16.61%	-27.95%	-35.40%	297.68%	-135.44%	108.92%	1,146.96%	-170.55%	-182.67%	117.37%
Invested Capital Q/Q Growth	-0.79%	-0.25%	-0.82%	-0.09%	-1.67%	1.22%	-0.91%	-0.65%	-0.39%	1.46%	-3.74%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	40.97%	39.95%	40.77%	41.01%	43.45%	41.90%	44.07%	44.62%	44.92%	43.59%	42.61%
EBITDA Margin	-5.48%	-12.13%	-6.93%	-3.58%	0.41%	-7.58%	-1.89%	-1.29%	0.05%	-5.53%	-16.20%
Operating Margin	-19.02%	-25.56%	-20.35%	-15.92%	-11.94%	-19.56%	-13.34%	-12.63%	-10.70%	-16.56%	-26.27%
EBIT Margin	-19.02%	-25.64%	-19.85%	-15.99%	-11.86%	-19.73%	-13.34%	-12.44%	-10.95%	-16.52%	-26.00%
Profit (Net Income) Margin	-16.36%	-22.44%	-16.56%	-12.19%	-9.21%	-17.32%	-11.33%	-10.55%	-8.91%	-15.43%	-24.87%
Tax Burden Percent	88.89%	91.33%	91.33%	86.32%	93.72%	97.76%	98.03%	99.16%	95.01%	101.04%	98.42%
Interest Burden Percent	96.74%	95.83%	91.35%	88.31%	82.85%	89.79%	86.67%	85.48%	85.64%	92.42%	97.18%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-6.11%	-8.54%	-7.16%	-5.86%	-4.58%	-7.71%	-5.45%	-5.31%	-4.66%	-7.25%	-12.07%
ROIC Less NNEP Spread (ROIC-NNEP)	-13.49%	-15.89%	-10.64%	-7.26%	-5.78%	-11.87%	-7.81%	-7.30%	-6.43%	-11.07%	-19.20%
Return on Net Nonoperating Assets (RNNOA)	-0.73%	-1.32%	-1.04%	-0.84%	-0.66%	-1.70%	-1.16%	-1.13%	-0.97%	-2.06%	-3.58%
Return on Equity (ROE)	-6.84%	-9.86%	-8.20%	-6.70%	-5.24%	-9.41%	-6.62%	-6.45%	-5.63%	-9.32%	-15.65%
Cash Return on Invested Capital (CROIC)	-7.23%	-5.79%	-5.81%	-5.44%	-4.13%	-5.27%	-4.72%	-3.99%	-5.33%	-5.31%	-4.26%
Operating Return on Assets (OROA)	-5.37%	-7.68%	-6.28%	-5.35%	-4.10%	-7.20%	-5.02%	-4.83%	-4.36%	-6.85%	-11.80%
Return on Assets (ROA)	-4.62%	-6.72%	-5.24%	-4.08%	-3.19%	-6.32%	-4.27%	-4.09%	-3.55%	-6.40%	-11.29%
Return on Common Equity (ROCE)	-6.84%	-9.86%	-8.20%	-6.70%	-5.24%	-9.41%	-6.62%	-6.45%	-5.63%	-9.32%	-15.65%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-12.89%	-11.99%	-10.17%	0.00%	-9.12%	-8.58%	-8.56%	0.00%	-8.73%	0.00%
Net Operating Profit after Tax (NOPAT)	-18	-25	-21	-17	-13	-21	-15	-15	-13	-19	-33
NOPAT Margin	-13.31%	-17.89%	-14.24%	-11.15%	-8.36%	-13.69%	-9.34%	-8.84%	-7.49%	-11.59%	-18.39%
Net Nonoperating Expense Percent (NNEP)	7.37%	7.35%	3.49%	1.40%	1.20%	4.16%	2.35%	1.99%	1.76%	3.82%	7.13%
Return On Investment Capital (ROIC_SIMPLE)	-1.20%	-	-	-	-0.88%	-	-	-	-0.89%	-1.36%	-2.79%
Cost of Revenue to Revenue	59.03%	60.05%	59.23%	58.99%	56.55%	58.10%	55.93%	55.38%	55.08%	56.41%	57.39%
SG&A Expenses to Revenue	39.56%	44.85%	41.05%	40.46%	38.42%	42.11%	38.50%	39.90%	37.00%	40.59%	39.57%
R&D to Revenue	4.81%	5.39%	5.11%	3.48%	4.58%	4.88%	4.79%	4.58%	4.63%	6.06%	4.98%
Operating Expenses to Revenue	59.99%	65.51%	61.11%	56.93%	55.39%	61.47%	57.41%	57.25%	55.62%	60.15%	68.87%
Earnings before Interest and Taxes (EBIT)	-26	-35	-29	-24	-18	-31	-22	-21	-19	-28	-47
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-7.60	-17	-10	-5.44	0.63	-12	-3.11	-2.17	0.09	-9.30	-29
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.17	2.28	2.14	1.66	2.19	2.17	1.93	2.08	2.34	1.37	1.10
Price to Tangible Book Value (P/TBV)	17.42	42.49	47.98	36.70	45.19	55.85	48.25	50.54	53.03	35.66	33.48
Price to Revenue (P/Rev)	2.29	4.19	3.72	2.73	3.49	3.28	2.82	2.93	3.20	1.81	1.37
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.15	2.14	2.01	1.57	2.05	2.00	1.80	1.93	2.15	1.31	1.08
Enterprise Value to Revenue (EV/Rev)	2.48	4.41	3.95	2.96	3.69	3.53	3.06	3.17	3.44	2.09	1.62
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	7,284.70	136.13	323.17	184.32	79.59
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.54	0.55	0.56	0.57	0.57	0.58	0.59	0.60	0.60	0.61	0.40
Long-Term Debt to Equity	0.54	0.55	0.56	0.57	0.57	0.58	0.37	0.37	0.38	0.38	0.40
Financial Leverage	0.05	0.08	0.10	0.12	0.11	0.14	0.15	0.16	0.15	0.19	0.19
Leverage Ratio	1.71	1.73	1.74	1.75	1.76	1.76	1.78	1.79	1.80	1.79	1.72
Compound Leverage Factor	1.66	1.65	1.59	1.55	1.46	1.58	1.55	1.53	1.54	1.65	1.67
Debt to Total Capital	34.91%	35.49%	35.95%	36.20%	36.37%	36.85%	37.08%	37.30%	37.49%	37.89%	28.54%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	13.75%	13.84%	13.91%	14.06%	0.00%
Long-Term Debt to Total Capital	34.91%	35.49%	35.95%	36.20%	36.37%	36.85%	23.33%	23.47%	23.58%	23.82%	28.54%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	65.09%	64.51%	64.05%	63.80%	63.63%	63.15%	62.92%	62.70%	62.51%	62.11%	71.46%
Debt to EBITDA	-6.26	-7.89	-9.63	-13.48	-17.01	-20.09	-27.32	-32.79	-31.79	-37.41	-8.37
Net Debt to EBITDA	-1.14	-1.74	-2.29	-3.39	-3.89	-5.74	-7.69	-9.26	-9.06	-12.69	-4.35
Long-Term Debt to EBITDA	-6.26	-7.89	-9.63	-13.48	-17.01	-20.09	-17.19	-20.63	-19.99	-23.53	-8.37
Debt to NOPAT	-4.85	-5.44	-5.86	-6.65	-7.14	-7.46	-8.09	-8.37	-8.39	-8.66	-4.24
Net Debt to NOPAT	-0.88	-1.20	-1.39	-1.67	-1.63	-2.13	-2.28	-2.36	-2.39	-2.94	-2.20
Long-Term Debt to NOPAT	-4.85	-5.44	-5.86	-6.65	-7.14	-7.46	-5.09	-5.26	-5.28	-5.45	-4.24
Altman Z-Score	1.41	2.25	2.10	1.74	2.14	2.12	1.76	1.85	2.03	1.30	1.28
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.73	6.75	6.16	6.32	6.20	7.48	2.01	1.99	1.98	2.05	3.92
Quick Ratio	6.20	6.20	5.64	5.76	5.67	6.85	1.84	1.82	1.78	1.82	3.16
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	12	9.63	6.94	4.48	18	-6.32	0.56	7.02	-4.96	-14	2.43
Operating Cash Flow to CapEx	-81.27%	-127.85%	-20.66%	-128.61%	252.01%	-464.01%	106.22%	85.62%	84.49%	-562.82%	321.52%
Free Cash Flow to Firm to Interest Expense	2.21	5.48	3.89	2.66	10.60	-3.75	0.34	4.28	-3.05	-8.66	2.61
Operating Cash Flow to Interest Expense	-0.71	-7.22	-0.87	-3.26	10.58	-15.38	8.34	5.63	6.03	-15.65	21.79
Operating Cash Flow Less CapEx to Interest Expense	-1.58	-12.87	-5.07	-5.80	6.38	-18.69	0.49	-0.95	-1.11	-18.43	15.01
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.28	0.30	0.32	0.33	0.35	0.36	0.38	0.39	0.40	0.41	0.45
Accounts Receivable Turnover	4.40	4.61	4.66	4.70	4.72	4.71	4.62	4.54	4.69	4.61	4.60
Inventory Turnover	13.50	13.48	14.15	14.25	14.33	15.88	14.97	14.99	14.56	14.95	13.47
Fixed Asset Turnover	4.81	5.00	5.22	5.71	6.08	6.40	6.54	6.87	7.10	7.58	7.76
Accounts Payable Turnover	16.75	15.06	19.06	22.34	16.99	17.32	20.54	21.82	17.67	21.68	17.30
Days Sales Outstanding (DSO)	83.01	79.11	78.31	77.67	77.41	77.44	79.02	80.49	77.85	79.12	79.36
Days Inventory Outstanding (DIO)	27.03	27.08	25.79	25.61	25.47	22.98	24.39	24.34	25.08	24.41	27.09
Days Payable Outstanding (DPO)	21.79	24.23	19.15	16.34	21.48	21.08	17.77	16.73	20.66	16.84	21.09
Cash Conversion Cycle (CCC)	88.25	81.96	84.95	86.95	81.40	79.34	85.63	88.10	82.26	86.69	85.36
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,095	1,093	1,084	1,083	1,065	1,078	1,068	1,061	1,057	1,072	1,032
Invested Capital Turnover	0.46	0.48	0.50	0.53	0.55	0.56	0.58	0.60	0.62	0.63	0.66
Increase / (Decrease) in Invested Capital	-30	-34	-28	-21	-31	-15	-16	-22	-7.93	-5.47	-36
Enterprise Value (EV)	1,264	2,337	2,178	1,704	2,185	2,158	1,923	2,043	2,270	1,403	1,118
Market Capitalization	1,167	2,219	2,050	1,569	2,062	2,004	1,771	1,890	2,115	1,219	941
Book Value per Share	$7.90	$7.65	$7.50	$7.43	$7.39	$7.32	$7.17	$7.09	$7.03	$6.91	$6.64
Tangible Book Value per Share	$0.53	$0.41	$0.34	$0.34	$0.36	$0.28	$0.29	$0.29	$0.31	$0.27	$0.22
Total Capital	1,533	1,510	1,493	1,485	1,480	1,462	1,456	1,449	1,443	1,430	1,195
Total Debt	535	536	537	537	538	539	540	540	541	542	341
Total Long-Term Debt	535	536	537	537	538	539	340	340	340	341	341
Net Debt	97	118	127	135	123	154	152	153	154	184	177
Capital Expenditures (CapEx)	4.53	9.93	7.49	4.27	7.06	5.59	13	11	12	4.50	6.32
Debt-free, Cash-free Net Working Capital (DFCFNWC)	77	80	81	92	85	112	106	106	109	137	129
Debt-free Net Working Capital (DFNWC)	515	498	490	494	501	497	494	494	496	495	292
Net Working Capital (NWC)	515	498	490	494	501	497	294	294	295	294	292
Net Nonoperating Expense (NNE)	4.22	6.24	3.41	1.58	1.32	5.66	3.28	2.86	2.44	6.45	12
Net Nonoperating Obligations (NNO)	97	118	127	135	123	154	152	153	154	184	178
Total Depreciation and Amortization (D&A)	19	19	19	19	19	19	19	19	19	18	18
Debt-free, Cash-free Net Working Capital to Revenue	15.18%	15.19%	14.60%	15.96%	14.42%	18.40%	16.95%	16.53%	16.46%	20.42%	18.68%
Debt-free Net Working Capital to Revenue	101.10%	94.08%	88.81%	85.95%	84.60%	81.42%	78.68%	76.73%	75.02%	73.68%	42.43%
Net Working Capital to Revenue	101.10%	94.08%	88.81%	85.95%	84.60%	81.42%	46.84%	45.62%	44.63%	43.76%	42.43%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.18)	($0.25)	($0.19)	($0.15)	$0.00	($0.21)	$0.00	($0.14)	$0.00	($0.20)	$0.00
Adjusted Weighted Average Basic Shares Outstanding	124.22M	125.03M	125.36M	125.69M	125.50M	126.11M	126.41M	126.95M	126.66M	127.38M	127.95M
Adjusted Diluted Earnings per Share	($0.18)	($0.25)	($0.19)	($0.15)	$0.00	($0.21)	$0.00	($0.14)	$0.00	($0.20)	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	124.22M	125.03M	125.36M	125.69M	125.50M	126.11M	126.41M	126.95M	126.66M	127.38M	127.95M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	127.46M	127.58M	127.55M	127.47M	127.61M	127.71M	128.16M	128.36M	128.46M	128.69M	129.18M
Normalized Net Operating Profit after Tax (NOPAT)	-15	-21	-19	-15	-12	-20	-14	-14	-12	-19	-19
Normalized NOPAT Margin	-11.04%	-15.50%	-12.78%	-10.17%	-7.82%	-12.62%	-8.68%	-8.42%	-6.79%	-11.59%	-10.65%
Pre Tax Income Margin	-18.40%	-24.57%	-18.13%	-14.12%	-9.83%	-17.72%	-11.56%	-10.64%	-9.38%	-15.27%	-25.27%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-5.06	-20.03	-16.35	-14.42	-10.98	-18.30	-13.17	-12.72	-11.60	-17.16	-50.53
NOPAT to Interest Expense	-3.54	-13.97	-11.73	-10.05	-7.73	-12.70	-9.22	-9.04	-7.93	-12.04	-35.73
EBIT Less CapEx to Interest Expense	-5.93	-25.68	-20.55	-16.95	-15.17	-21.61	-21.02	-19.29	-18.74	-19.94	-57.31
NOPAT Less CapEx to Interest Expense	-4.41	-19.62	-15.93	-12.59	-11.93	-16.01	-17.07	-15.61	-15.07	-14.82	-42.51
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Key Financial Trends

NeoGenomics (NASDAQ: NEO) has experienced steady growth in operating revenue over the last four years, increasing from approximately $125 million in Q2 2022 to $181 million in Q2 2025. This consistent increase demonstrates strong demand and market expansion in their specialized diagnostic services.

Positive financial trends:

Steady revenue growth: Operating revenue increased approximately 45% from $125M in Q2 2022 to $181M in Q2 2025, indicating strong business expansion.
Improved gross profit margin: Gross profit rose consistently, reaching about $77 million in Q2 2025, supporting operational efficiency gains.
Strong cash position: Despite net losses, NeoGenomics retains substantial cash and equivalents ($155M at Q2 2025), providing liquidity for operations and investments.
Ongoing investments: Continued purchase of property, plant & equipment signals investment in capacity and technology enhancement ($6.3M in Q2 2025).
Non-cash expenses such as depreciation and amortization remain significant, reflecting heavy investment in intangible assets, which can support long-term growth.

Neutral observations:

Accounts receivable remain high (around $153M in Q2 2025), consistent with growing revenues but requiring continued management focus on collections.
Intangible assets and goodwill have remained largely stable, reflecting the company’s investments in acquisitions or internal development without impairments in the latest quarter.
Weighted average shares outstanding have remained relatively steady, suggesting limited dilution year over year.
Marketing and R&D expenses have increased but remain proportionate to revenue growth, indicating stable investment levels in growth initiatives.

Negative financial trends and risks:

Consistent net losses: The company has reported net losses every quarter, including a consolidated net loss of $45.1 million in Q2 2025, with operating losses increasing year over year.
Rising operating expenses: Total operating expenses have increased to about $125 million in Q2 2025, driven by impairment charges ($20M in Q2 2025) and restructuring costs, which pressures profitability.
Significant debt load: Long-term debt stands at approximately $341 million as of Q2 2025, which could pose financial risk especially amid continuing losses.
Cash flow from financing activities is heavily negative in Q2 2025 (-$202 million), possibly indicating repayment or lack of new financing compared to prior inflows.
Negative cash flow from operating activities in prior quarters shows ongoing operational cash challenges, requiring careful cash management to sustain growth and operations.

In summary, NeoGenomics demonstrates solid revenue growth and investment in its business infrastructure, which are positive indicators for future expansion. However, persistent net losses, rising expenses including impairment charges, and high debt levels present significant challenges. Investors should weigh these factors carefully, considering the company’s path to profitability and capital structure management over the coming quarters.

08/16/25 02:14 PMAI Generated. May Contain Errors.

Frequently Asked Questions About NeoGenomics' Financials

When does NeoGenomics' financial year end?

According to the most recent income statement we have on file, NeoGenomics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has NeoGenomics' net income changed over the last 10 years?

NeoGenomics' net income appears to be on an upward trend, with a most recent value of -$78.73 million in 2024, falling from $1.13 million in 2014. The previous period was -$87.97 million in 2023. Check out NeoGenomics' forecast to explore projected trends and price targets.

What is NeoGenomics' operating income?

NeoGenomics' total operating income in 2024 was -$92.11 million, based on the following breakdown:

Total Gross Profit: $290.10 million
Total Operating Expenses: $382.21 million

How has NeoGenomics' revenue changed over the last 10 years?

Over the last 10 years, NeoGenomics' total revenue changed from $87.07 million in 2014 to $660.57 million in 2024, a change of 658.7%.

How much debt does NeoGenomics have?

NeoGenomics' total liabilities were at $735.70 million at the end of 2024, a 0.5% decrease from 2023, and a 3,453.9% increase since 2014.

How much cash does NeoGenomics have?

In the past 10 years, NeoGenomics' cash and equivalents has ranged from $9.81 million in 2018 to $367.01 million in 2024, and is currently $367.01 million as of their latest financial filing in 2024.

How has NeoGenomics' book value per share changed over the last 10 years?

Over the last 10 years, NeoGenomics' book value per share changed from 1.01 in 2014 to 7.03 in 2024, a change of 597.9%.

Related Companies

This page (NASDAQ:NEO) was last updated on 8/16/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NeoGenomics (NEO) Financials

Key Financial Trends

Frequently Asked Questions About NeoGenomics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NeoGenomics (NEO) Financials

Annual Income Statements for NeoGenomics

Quarterly Income Statements for NeoGenomics

Annual Cash Flow Statements for NeoGenomics

Quarterly Cash Flow Statements for NeoGenomics

Annual Balance Sheets for NeoGenomics

Quarterly Balance Sheets for NeoGenomics

Annual Metrics And Ratios for NeoGenomics

Quarterly Metrics And Ratios for NeoGenomics

Key Financial Trends

Frequently Asked Questions About NeoGenomics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools